Clinical Trial Update: Modulation of Response to Hormonal Therapy With Lapatinib and/or Metformin in Patients With Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study investigating modulation of response to hormonal therapy with lapatinib and/or metformin in metastatic breast cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Lapatinib (Lapatinib)
• metformin (metformin)

Snippet

Sponsor: Fondazione Michelangelo | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED